| abstract |
Novel variants of the first Kunitz domain (K 1 ) of human lipoprotein binding aggregation inhibitor (LACI) that inhibits plasmin, and other modified Kunitz domains that inhibit plasmin, and other plasmins To provide an inhibitor. A variant of the BPTI homologous Kunitz domain effective for the inhibition of human plasmin, particularly a variant of one domain of human LACI that is non-immunogenic to humans, preferably about 5 nM or less, more preferably about 300pM or less, and most preferably capable of inhibiting plasmin of about 100pM or less of K D, treatment, it can be used for diagnosis. [Selection figure] None |